Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/8/2024 | $30.00 → $31.00 | Buy → Hold | Truist | |
7/19/2024 | $3.00 → $4.00 | Neutral | Citigroup | |
4/2/2024 | $5.00 → $1.50 | Buy → Underperform | BofA Securities | |
12/19/2023 | $22.00 | Buy | Jefferies | |
12/19/2023 | $3.11 | Hold | Jefferies | |
11/30/2023 | $8.00 → $3.00 | Outperform → Neutral | Robert W. Baird | |
11/29/2023 | Overweight → Equal Weight | Wells Fargo | ||
9/29/2023 | Peer Perform | Wolfe Research |
4 - PetIQ, Inc. (0001668673) (Issuer)
4/A - PetIQ, Inc. (0001668673) (Issuer)
4 - PETMED EXPRESS INC (0001040130) (Issuer)
DELRAY BEACH, Fla., Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of retail and ecommerce veteran Robyn D'Elia as Chief Financial Officer ("CFO") effective September 16, 2024. D'Elia brings over 25 years of experience in financial leadership and strategic planning across multiple industries, including 24 years at Bed Bath & Beyond where she served in senior leadership roles across finance for two decades, and served as CFO from 2018 to 2020. Most recently D'Elia served as CFO at Odeko, a privately held all-in-one operations partner for independent coffee shops, cafes and ot
DELRAY BEACH, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of Doug Krulik as Chief Accounting Officer (CAO) effective August 19, 2024. Krulik comes to PetMeds with more than 20 years of leadership experience in finance and accounting, most recently with Etherio Holdings as its Vice President Finance and Controller. In this newly created role, he will oversee all aspects of the Company's accounting functions, including financial reporting, treasury, tax, compliance, and internal controls. Krulik will report directly to the Office of the Chief Financial Officer. "Doug'
30-Year Retail Industry Veteran Named Chief Executive Officer and Member of the Board of Directors R. Michael Mohan to Lead a New Board Committee Focused on Value Creation SAN DIEGO, July 17, 2024 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) today announced that the Company's Board of Directors has appointed Joel D. Anderson to serve as Chief Executive Officer (CEO), effective July 29, 2024. In addition, Anderson has been elected to serve on the Company's Board of Directors. "Joel is an inspirational leader and a highly experienced retail CEO," said Gl
4 - Petco Health & Wellness Company, Inc. (0001826470) (Issuer)
4 - Petco Health & Wellness Company, Inc. (0001826470) (Issuer)
4 - PETMED EXPRESS INC (0001040130) (Issuer)
Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously
Citigroup reiterated coverage of Petco Health and Wellness with a rating of Neutral and set a new price target of $4.00 from $3.00 previously
BofA Securities downgraded Petco Health and Wellness from Buy to Underperform and set a new price target of $1.50 from $5.00 previously
DELRAY BEACH, Fla., Sept. 12, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS) (the "Company") today announced the appointment of retail and ecommerce veteran Robyn D'Elia as Chief Financial Officer ("CFO") effective September 16, 2024. D'Elia brings over 25 years of experience in financial leadership and strategic planning across multiple industries, including 24 years at Bed Bath & Beyond where she served in senior leadership roles across finance for two decades, and served as CFO from 2018 to 2020. Most recently D'Elia served as CFO at Odeko, a privately held all-in-one operations partner for independent coffee shops, cafes and ot
Q2 2024 Overview Net revenue of $1.52 billion decreased 0.5 percent year over year Comparable sales increased 0.3 percent year over year and increased 3.5 percent on a two-year basis GAAP net loss of $24.8 million, or $(0.09) per share, compared to GAAP net loss of $14.6 million, or $(0.05) per share in the prior yearAdjusted EBITDA1 of $83.5 million compared to $112.6 million in the prior yearOperating Cash Flow of $69.4 million compared to $96.6 million in the prior yearFree Cash Flow 1 of $42.0 million compared to $44.6 million in the prior yearSAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (NASDAQ:WOOF), a complete partner in pet health and wellness, to
DELRAY BEACH, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (NASDAQ:PETS), will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference, to be held September 4-6, 2024 in New York. Sandra Campos, CEO and President, will hold a fireside chat on September 6, 2024 at 7:45 a.m. (Eastern Time). A live audio webcast of the fireside chat will be available on the "Events & Presentations" section of PetMed's investor relations website at https://investors.petmeds.com. After the event, a replay of the fireside chat will be archived and available on this same website for approximately 90 days. About PetMed Express, Inc.
Citigroup analyst Steven Zaccone maintains Petco Health and Wellness (NASDAQ:WOOF) with a Neutral and raises the price target from $3 to $4.
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Petco Health and Wellness (NASDAQ:WOOF) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 3 1 0 0 3M Ago 0 0 1 0 0 Analysts have recently evaluated Petco Health and Wellness and provided 12-month price targets. The average target is $3.71, accompanied by a high estimate of $5.00 and a low estimate of $
Wedbush analyst Seth Basham maintains Petco Health and Wellness (NASDAQ:WOOF) with a Outperform and raises the price target from $4 to $5.
DEFM14A - PetIQ, Inc. (0001668673) (Filer)
8-K - PETMED EXPRESS INC (0001040130) (Filer)
10-Q - Petco Health & Wellness Company, Inc. (0001826470) (Filer)
Q2 2024 Overview Net revenue of $1.52 billion decreased 0.5 percent year over year Comparable sales increased 0.3 percent year over year and increased 3.5 percent on a two-year basis GAAP net loss of $24.8 million, or $(0.09) per share, compared to GAAP net loss of $14.6 million, or $(0.05) per share in the prior yearAdjusted EBITDA1 of $83.5 million compared to $112.6 million in the prior yearOperating Cash Flow of $69.4 million compared to $96.6 million in the prior yearFree Cash Flow 1 of $42.0 million compared to $44.6 million in the prior yearSAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (NASDAQ:WOOF), a complete partner in pet health and wellness, to
Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati
DELRAY BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:PETS) today announced its financial results for its first quarter ended June 30, 2024. Quarterly Highlights for Q1, Fiscal 2025 Net sales were $68 million, (13)% lower than the prior year comparable quarter.Net income was $3.8 million, or $0.18 diluted earnings per share. This compares to net loss of $(1.1) million, or $(0.06) diluted earnings per share, for the prior year comparable quarter.Increase in net income is primarily attributed to a $8.7 million reversal of accumulated stock compensation expense associated with departure of the former CEO, partially off
SC 13G - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - PetIQ, Inc. (0001668673) (Subject)
SC 13G/A - Petco Health & Wellness Company, Inc. (0001826470) (Subject)